MBRX vs SNOW · $8.2M cap vs rev $1.55B
Moleculin Biotech Inc (MBRX) versus Snowflake Inc. (SNOW) — a side-by-side from cached financials, not a winner call.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Snowflake Inc. (SNOW) is a software - application company listed on US.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
Latest reported SNOW revenue for 2026-07-31 was $1.55B. Net income was -$191.7M. Revenue was up 11.2% from 2026-04-30 to 2026-07-31. SNOW currently screens at market cap $73.90B.
MBRX currently screens at market cap $8.2M. SNOW currently screens at market cap $73.90B.
Not investment advice. Open the MBRX and SNOW stock pages for the full models.
Not investment advice.